Livagen
Lys-Glu-Asp-Ala tetrapeptide (KEDA)
A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) studied mainly in ex vivo elderly lymphocyte cultures and animal liver models, where it induced chromatin decondensation and ribosomal gene reactivation, but no clinical trials exist (PMID 12533768; PMID 16705247; raw).
Last updated: 2026-03-09
Safety Summary
No peer-reviewed safety data, dedicated toxicology studies, FDA labels, or FAERS case records exist for Livagen (raw, raw). All side effect information above comes from vendor pages and community anecdotes, which are not substitutes for clinical pharmacovigilance. Peptide Initiative reports adverse events in less than 5% of patients from Eastern European clinical use spanning 20+ years (peptideinitiative.com via Tavily safety), but this claim could not be verified against primary clinical data. Preclinical rodent studies reportedly showed no observable toxic effects at low-to-moderate doses with repeated dosing for up to 30 days (rcpeptides.com via Tavily safety). One online communities user reported severe anxiety and cardiac palpitations lasting several months after a 12-day protocol (rcpeptides.com via Tavily safety citing). No data on drug-drug interactions, pharmacokinetics, or carcinogenic risk exists. The absence of carcinogenicity or mutagenicity data is a notable gap given that the peptide's mechanism involves chromatin remodeling which could theoretically unmask oncogenes.
Known Side Effects
common
uncommon
uncommon
rare
rare
Who Should NOT Use This
Chromatin decondensation and gene reactivation could theoretically reactivate silenced oncogenes and promote tumor growth. No safety data in cancer patients exists. The breast cancer lymphocyte study (PMID 28574395) showed Livagen had protective effects on lymphocyte genomic parameters, but this does not address direct effects on tumor cells. This is a theoretical concern based on mechanism, not a formally established contraindication (rcpeptides.com via Tavily safety).
No reproductive safety data exists in any species in the source set. Standard precautionary principle for any compound that modulates chromatin structure and gene expression.
Theoretical concern: immune stimulation via lymphocyte activation and chromatin remodeling could exacerbate autoimmune conditions. No clinical data exists to confirm or refute this.
Theoretical concern: potential pharmacological conflict between Livagen's immune-activating chromatin remodeling effects and immunosuppressive drug mechanisms. No interaction studies exist.
Talk to Your Doctor
Before considering Livagen, discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-20]
Evidence Assessment
Tier 5 -- Preclinical only (animal, in vitro, and ex vivo). Although the chromatin decondensation studies (PMID 12533768, PMID 15085253, PMID 16705247, PMID 37042594) use human lymphocytes from elderly donors aged 75-88, these are ex vivo laboratory studies in which cells were extracted and treated in culture -- no human subject received Livagen as a treatment. The enkephalin-degrading enzyme inhibition study (PMID 12942748) used human serum in vitro. Animal studies include rat hepatocyte cultures (PMID 15926314), rat digestive enzyme studies (PMID 16075683), and liver pathology models (PMID 32362099). No registered clinical trials exist (raw returns 0 results). No dose-ranging studies in humans. No pharmacokinetic data in humans. Nearly all research originates from the Khavinson-Lezhava research axis. No independent Western replication. The ex vivo human lymphocyte data places Livagen at the upper boundary of Tier 5, closer to Tier 4 than most purely animal-study peptides.
1Tissue-specific effects of peptides.PMID 11713572
Khavinson V Kh - Bulletin of Experimental Biology and Medicine (2001) - in vitro (organotypic culture) - Rat tissue explants (brain cortex, subcortical structures, liver, thymus); N not stated
Livagen specifically stimulated growth of liver explants in organotypic cultures, demonstrating tissue-specific effects matching the source organ (liver) of its parent polypeptide complex (Hepalin). Other cytogens (Cortagen, Epithalon, Vilon) showed corresponding tissue specificity for brain cortex, subcortical structures, and thymus respectively.
Limitations: In vitro. No quantification of growth stimulation provided in abstract. Single research group (Khavinson). N not stated.
2[Tissue-specific action of peptides in tissue culture of rats of various ages].PMID 12096446
Not specified in abstract - Russian-language journal (2002) - in vitro (organotypic culture) - Rat tissue explants of various ages; N not stated
Livagen and other peptides (Cortagen, Epitalon, Vilon) and their parent polypeptide complexes exerted tissue-specific effects in organotypic culture of animal tissues at applied concentrations.
Limitations: Russian-language publication. Single research group. No quantitative data in abstract. N not stated.
3Effects of Livagen peptide on chromatin activation in lymphocytes from old people.PMID 12533768
Khavinson V Kh, Lezhava T A, Monaselidze J G et al. - Bulletin of Experimental Biology and Medicine (2002) - ex vivo (human lymphocyte culture) - Lymphocytes from elderly donors; N not stated
Livagen induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes repressed due to age-related condensation of euchromatic regions. Results indicate Livagen causes de-heterochromatinization via modification of heterochromatin and heterochromatinized regions in chromosomes from old people.
Limitations: Single research group (Khavinson-Lezhava). N not specified. No control peptide comparison. Ex vivo only.
4[Functional morphology of an organotypic liver culture exposed to the peptide livagen].PMID 12577697
Not specified in abstract - Russian-language journal (2002) - in vitro (liver organotypic culture) - Liver culture; N not stated
Livagen stimulated structural and functional homeostasis of cell populations in liver culture. Immunocytochemical and morphometric analysis showed the peptide stabilized morphological integrity and reinforced cellular and intracellular forms of regeneration.
Limitations: Russian-language publication. In vitro only. Single research group. N not stated.
5[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].PMID 12942748
Kost N V, Sokolov O Yu, Gabaeva M V et al. - Izvestiia Akademii nauk. Seriia biologicheskaia (2003) - in vitro (human serum) - Human serum samples and rat brain membrane fractions; N not stated
Livagen inhibited enkephalin-degrading enzymes in human serum with IC50 = 20 microM. More efficient than puromycin, leupeptin, and D-PAM. Epitalon IC50 = 500 microM. Neither peptide interacted with mu- or delta-opioid receptors in rat brain membrane fractions.
Limitations: In vitro only. Russian-language publication. Single study. No in vivo confirmation of enkephalin elevation. N not stated.
6Effects of short peptides on lymphocyte chromatin in senile subjects.PMID 15085253
Khavinson V Kh, Lezhava T A, Malinin V V - Bulletin of Experimental Biology and Medicine (2004) - ex vivo (human lymphocyte culture) - Leukocytes from subjects aged 75-88 years; N not stated
All five tested peptides (Vilon, Epithalon, Livagen, Prostamax, Cortagen) induced activation of ribosome genes, decondensation of densely packed chromatin fibrils, and release of genes repressed by age-specific condensation. Specifically, Epithalon, Livagen, and Prostamax led to decondensation of chromosome 1 pericentromeric structural chromatin, while Epithalon and Livagen affected chromosome 9 as well.
Limitations: Same research group. N not quantified. No placebo/sham control described. Ex vivo only.
7[Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen].PMID 15926314
Not specified in abstract - Russian-language journal (2001) - in vitro (rat hepatocyte culture) - Hepatocytes from rats aged 1 to 24 months; N not stated
Livagen increased the level of protein synthesis in hepatocytes from rats of different ages, with highest effect in cells of old animals. In old rats, Livagen increased the amplitude of protein synthesis fluctuations (circumhoralian rhythm). Control peptide Epitalon did not change protein synthesis intensity in hepatocyte cultures, confirming tissue specificity.
Limitations: Russian-language publication. In vitro only. Animal model. Single research group. N not stated.
8[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].PMID 16075683
Not specified in abstract - Russian-language journal (2005) - animal study (rats, in vivo + in vitro) - Young and old rats; N not stated
Livagen is weakly hydrolyzed -- small intestinal peptide hydrolases do not hydrolyze it. In vitro, Livagen reduces glycyl-L-leucinedipeptidase activity in small intestine by 50%. After two weeks oral administration: digestive enzyme activity decreased in young animals but increased in old animals, with old rat enzyme levels approaching those of young controls.
Limitations: Russian-language. Animal model. N not specified. Dose not reported. Single research group.
9Anti-aging peptide bioregulators induce reactivation of chromatin.PMID 16705247
Lezhava T, Monaselidze J, Kadotani T et al. - Georgian Medical News (2006) - ex vivo (human lymphocyte culture) - Lymphocytes from individuals aged 75-88 years; N not stated
Epitalon, Livagen, and Vilon all: (1) activate synthetic processes via ribosomal gene deheterochromatinization; (2) induce total heterochromatin unrolling; (3) release genes repressed by facultative heterochromatin. Epitalon and Livagen specifically induce decondensation of pericentromeric structural heterochromatin of chromosomes 1 and 9, while Vilon does not -- demonstrating selective action.
Limitations: Lezhava research group (Georgia). N not quantified. Published in Georgian Medical News. Ex vivo only.
10Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.PMID 17460203
Lezhava Teimuraz, Jokhadze Tina - Annals of the New York Academy of Sciences (2007) - ex vivo (human lymphocyte culture) - Lymphocytes from 80-91 year-olds (test) and 18-30 year-olds (control); N not stated
Livagen induced chromatin reactivation (deheterochromatinization) in cultured lymphocytes of aged individuals. CoCl2 caused significant increase in chromosomal aberrations in old donors vs control (P < 0.05). Livagen decreased CoCl2-induced aberrations to 3.4 +/- 0.6% (control 4.2 +/- 0.7%). CoCl2 alone targeted pericentromeric heterochromatin (15.4 +/- 1.8% SCE), while CoCl2 + Livagen shifted SCE to telomeric regions.
Limitations: Lezhava group. Ex vivo only. N not specified. Published in Annals of NYAS (peer-reviewed).
11[Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen].PMID 17921545
Not specified in abstract - Russian-language journal (2007) - ex vivo (human lymphocyte culture) - PHA-stimulated cells from 72-86 year-olds; control: 30-40 year-olds; N not stated
Cells from aged individuals maintained radiation adaptive response. Preliminary radiation exposure stimulated adaptive response in copper-treated cells. Livagen showed corrective activity on radiation-adaptive response.
Limitations: Russian-language. Abstract does not provide quantitative data. Small study from the same research axis. N not stated.
12[The effect of heavy metal ions and peptide bioregulators on the expression of chromosome fragile sites in the individuals of different age groups and breast cancer patients].PMID 18830022
Not specified in abstract - Russian-language journal (2008) - ex vivo (human lymphocyte culture) - Clinically healthy young (20-38 yrs) and old (75-86 yrs) groups; 8 breast cancer patients
Livagen and Epithalon lessened the effect of heavy metals (nickel, zinc, cobalt) on chromosome fragile site expression. Effect was statistically reliable only in the young people group. Breast cancer patients showed elevated overall chromosomal fragility.
Limitations: Small sample (8 cancer patients). Statistical significance only in young group. Russian-language. Same research axis.
13Gerontology research in Georgia.PMID 20480236
Lezhava Teimuraz et al. - Biogerontology (2011) - review - N/A (review)
Comprehensive review of Georgian gerontology research. Documents that progressive chromosome heterochromatinization occurs in aging and may be reversible under the influence of bioregulators. States that Livagen can induce chromatin reactivation.
Limitations: Review paper, not primary data. Represents the Lezhava group perspective.
14[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].PMID 24423684
Not specified in abstract - Russian-language journal (2013) - ex vivo (human lymphocyte culture) - HCM patients and first-degree relatives; N not stated
HCM patients and relatives showed higher frequency of spontaneous chromosomal disorders. Epithalon showed the most effective protective action for lowering chromosomal instability. Livagen was tested but was not the most effective agent.
Limitations: Russian-language. Livagen was not the most effective agent tested. N not stated. Same research axis.
15[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].PMID 25341254
Not specified in abstract - Russian-language journal (2014) - ex vivo (human lymphocyte culture) - HCM patients and first-degree relatives; N not stated
Combined Livagen + cobalt ions increased frequency of large Ag-positive NORs and significantly increased associative activity of acrocentric chromosomes in both patients and relatives. Livagen + cobalt was more effective than Livagen alone.
Limitations: Russian-language. N not stated. Single research group. Ex vivo only.
16[Genomic instability in atherosclerosis].PMID 25541832
Not specified in abstract - Russian-language journal (2014) - ex vivo (human lymphocyte culture) - Atherosclerosis patients 80+ years old; control: 30-35 year-olds; N not stated
Atherosclerosis patients showed high genomic instability (aberrations, aneuploidy, polyploidy) regardless of age. Livagen alone and in combination with cobalt ions promoted normalization of altered genomic indicators in both age groups.
Limitations: Russian-language. Ex vivo lymphocyte study, not clinical cardiovascular outcomes. N not stated. Same research axis.
17[Evaluation of genomic parameters in ductal breast cancer patients and the ability of its correction].PMID 28574395
Jokhadze T, Gaiozishvili M, Buadze T et al. - Georgian Medical News (2017) - ex vivo (human lymphocyte culture) - Ductal breast cancer patients; N not stated
Breast cancer patients showed high density of DNA single-strand breaks, high chromosomal abnormalities, and increased chromatin condensation. Livagen and cobalt ions used as modifying agents showed protective effects across all studied parameters.
Limitations: Small implied sample. Ex vivo only, not tumor treatment. Georgian Medical News. Same research group.
18[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology].PMID 32362099
Not specified in abstract - Russian-language journal (2020) - review (animal and in vitro data) - N/A (review)
Review of hepatoprotective, immunoprotective, and anti-aging properties of liver polypeptide complex (Ventvil) and KEDA tetrapeptide (Livagen). In experimental models of liver fibrosis, acute and chronic hepatitis, both demonstrated high efficacy. Maximal hepato- and immunoprotective effects were observed in aging.
Limitations: Russian-language review. Based on animal models and in vitro data. Same research tradition.
19Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.PMID 35887081
Khavinson Vladimir, Linkova Natalia, Kozhevnikova Ekaterina et al. - International Journal of Molecular Sciences (2022) - review - N/A (review)
POT family transporters (PEPT1, PEPT2, PHT1, PHT2) transport di- and tripeptides into cells. LAT1 may also transfer some di- and tripeptides. This mechanism may underlie the tissue specificity and geroprotective action of ultrashort peptides including Livagen.
Limitations: Review paper from Khavinson's group. Does not specifically demonstrate Livagen transport via these carriers. Theoretical framework.
20Epigenetic modification under the influence of peptide bioregulators on the 'old' chromatin.PMID 37042594
Lezhava T, Jokhadze T, Monaselidze J et al. - Georgian Medical News (2023) - ex vivo (human lymphocyte culture) - Lymphocytes from 75-88 year-old individuals; N not stated
Tested four peptide bioregulators (Epitalon, Livagen, Cortagen, Vilon) on condensed chromatin. All induced deheterochromatinization of total heterochromatin and satellite stalks of acrocentric chromosomes, activating ribosomal genes. Each peptide had selective effects on specific chromosome regions. Used DSC, NOR activity, C-heterochromatin polymorphism, and SCE methods.
Limitations: Same Lezhava research group. Published in Georgian Medical News. N not quantified. Ex vivo only.